Senesys.Bio is a biotechnology company leading the development of novel senolytic delivery technologies to combat age-related diseases. Our flagship technology, NanoJAGGs, is a groundbreaking nanostructure-based delivery system designed to accurately detect and deliver senolytic drugs to senescent cells. Senescent or “”Zombie”” cells are damaged cells that accumulate with age and contribute to a wide range of age-related diseases, including Alzheimer’s, Parkinson’s, and cancer. While senolytic drugs have demonstrated remarkable efficacy in eliminating senescent cells in preclinical studies, their effectiveness is hampered by the lack of precise delivery methods. Current delivery methods often fail to target senescent cells effectively, resulting in limited therapeutic benefits and increased side effects.
NanoJAGGs address this challenge by leveraging their unique ability to specifically accumulate in senescent cell lysosomes, the cellular compartments where senolytic drugs exert their beneficial effects. Senescent cells exhibit increased lysosomal activity, creating an environment that readily attracts NanoJAGGs. As they are taken up by senescent cells, NanoJAGGs deliver their encapsulated senolytic drugs directly into the lysosomes at the precise location to aid effective elimination of senescent cells. Ultimately, senolytic drugs are delivered with greater precision, improving their efficacy, and reducing side effects. Senesys.Bio’s technology has the potential to transform the treatment of age-related diseases by providing a more effective and targeted approach to senolytic therapy.
Founding team
Ioannis Prattis
Ioannis Prattis completed his Ph.D., University of Cambridge in 2023, and is currently working as a Market Access and Health Economics Consultant at CITC-ltd. In this role, he provides critical insights and evidence-based recommendations for startups. Ioannis is involved with Senesys.Bio on a full-time basis as Chief Executive Officer, utilising his expertise to successfully commercialize Senesys.Bio’s technology.
Ioannis Prattis completed his Ph.D., University of Cambridge in 2023, and is currently working as a Market Access and Health Economics Consultant at CITC-ltd. In this role, he provides critical insights and evidence-based recommendations for startups. Ioannis is involved with Senesys.Bio on a full-time basis as Chief Executive Officer, utilising his expertise to successfully commercialize Senesys.Bio’s technology.